Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 1998

View Archived Issues

Amylin announces results from pramlintide phase III studies

UCB acquires CytoMed assets and development pipeline

AERx Diabetes Management System enters phase II trials

ICN obtains rights to Senetek skincare cosmeceutical

Senetek licenses autoinjectable drug delivery system to ICN

Antiprogestin with potential as an oral postcoital contraceptive in women

Prostaglandin analogues attenuate ischemic liver damage in canine model

Selective ETA or mixed ETA/ETB antagonist for CHF?

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

FDA clears first test for CMV DNA

Phase III study evaluates efficacy of tacrolimus in bone marrow transplantation

GlycoDesign and NRC agreement represents new approach to antibiotics

(+)-Enantiomer of known compound acts as potent, selective NMDA receptor antagonist

Novel class of vitamin D derivatives for metabolic bone diseases, psoriasis

Calpain inhibitors jointly developed by SKB and Cephalon

Difluoronucleoside antineoplastic and antiherpesvirus agents from Lilly

Astra's new antiasthmatic, antirhinitic agents

Thiocarbamic acid derivatives as inhibitors of squalene epoxidase

Positive initial clinical findings reported for first-generation GVAX vaccine for melanoma

AChE inhibition does not contribute to the neuroprotective effects of anseculin in vivo

Paralyzed mice regain the ability to walk following treatment with CM-101

Novel class of microtubule-destabilizing agents synthesized and evaluated at Kansas State

Addition of Remune increases efficacy of HAART in HIV-positive patients

CEA-Scan accurately detects breast cancer with low rate of false-positive results

European approval for Roche's sale of DePuy

CollaGenex seeks E.U.-wide approval of Periostat

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...